Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMIOUEY)

Drug Name
AMG 337 Drug Info
Indication
Disease Entry ICD 11 Status REF
Clear cell sarcoma 2A60-2C35 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
PubChem CID
44181686
CAS Number
CAS 1173699-31-4
TTD Drug ID
DMIOUEY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Proto-oncogene c-Met (MET) DTT MET 6.737 6.293 7.744 6.879
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Clear cell sarcoma
ICD Disease Classification 2A60-2C35
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Met (MET) DTT MET 1.08E-03 -0.24 -0.4
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health.
3 J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).